Previous Close | 0.7300 |
Open | 0.7162 |
Bid | 0.0000 x 3100 |
Ask | 0.0000 x 1400 |
Day's Range | 0.6600 - 0.7243 |
52 Week Range | 0.3500 - 2.3700 |
Volume | |
Avg. Volume | 2,522,390 |
Market Cap | 162.153M |
Beta (5Y Monthly) | 1.58 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2740 |
Earnings Date | Nov 01, 2022 - Nov 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for ASXC
RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its operating and financial results for the second quarter 2022. Recent Highlights Over 670 procedures were performed globally during the quarter, representing growth of 34% over the prior year quarter, including 77% growth in
Senhance System to be placed at hospital in the Commonwealth of Independent States Senhance Surgical System Performance-Guided Surgery™ Leveraging the Performance-Guided Surgery™ framework, the Senhance Surgical System advances clinical intelligence by providing surgeons with augmented intelligence and digital tools to perform consistently superior surgery. RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that
RESEARCH TRIANGLE PARK, N.C., July 26, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release 2022 second quarter financial and operating results after the market closes on Monday, August 8, 2022. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day.